TECHNE CORPORATION
HomeCompany NewsFinancial InformationAbout TechneMap - DirectionsProductsContact Us

Segment Results - 3 rd Quarter Fiscal Year 2007

TECHNE CORPORATION AND SUBSIDIARIES
(in thousands of $’s, except per share data)

  Fiscal 2007 Increase(Decrease) From Fiscal 2006
First Quarter Second Quarter Third Quarter YTD Percent Of Sales First Quarter Second Quarter Third Quarter YTD
Sales 52,351 52,509 60,197 165,057 100% 4,642 4,480 5,384 14,506
Cost of sales 11,237 10,714 12,019 33,970  21% 141 19   (86)       74
Gross margin 41,114 41,795 48,178 131,087 79% 4,501 4,461 5,470 14,432
                   
Gross margin percentage 78.5% 79.6% 80.0% 79.4%          
                   
SG&A expense 7,067 8,830 7,229 23,126 14% 613 850 328 1,791
R&D expense 4,855 5,044 5,169 15,068 9% 138 470 408 1,016
Amortization expense 403 404 403 1,210 1% (89) (88) (89) (266)
Interest expense 268 815 0 1,083 1% 45 577 (245) 377
Interest income (1,676) (1,956) (2,237) (5,869) (4%) (702) (826) (1,155) (2,683)
Othernon-operating exp., net 485 428      767    1,680     1% 274 147     538      959
  11,402 13,565 11,331  36,298  22% 279 1,130  (215)   1,194
Earnings before income taxes 29,712 28,230 36,847 94,789 57% 4,222 3,331 5,685 13,238
Income taxes 10,081 9,567 12,954 32,602  20% 1,592 1,182 2,139  4,913
  19,631 18,663 23,893  62,187  37% 2,630 2,149 3,546  8,325
                   
Diluted earnings per share .50 .47 .60 1.57          
Weighted average diluted shares outstanding 39,469 39,511 39,543 39,498          

Back to Top
HEMATOLOGY DIVISION
(in thousands of $’s)

  Fiscal 2007 Increase(Decrease) From Fiscal 2006
First Quarter Second Quarter Third Quarter YTD Percent Of Sales First Quarter Second Quarter Third Quarter YTD
Sales 3,502 3,826 3,664 10,992 100% (32) 45 (36) (23)
Cost of sales 2,098 2,147 2,085 6,330   58% (7) 13 (15)    (9)
Gross margin 1,404 1,679 1,579 4,662 42% (25) 32 (21) (14)
                 
Gross margin percentage 40.1% 43.9% 43.1% 42.4%          
                 
SG&A expense 398 439 431 1,268 12% 14 15 (10) 19
R&D expense 180 190 198 568 5% (5) 20 30 45
Interest, net (81) (95) (111) (287)  (3%) (44) (45) (71) (160)
497 534   518 1,549  14% (35) (10) (51)  (96)
Pretax result 907 1,145 1,061 3,113  28% 10 42    30    82

Back to Top
BIOTECHNOLOGY DIVISION (1)
(in thousands of $’s)

  Fiscal 2007 Increase(Decrease) From Fiscal 2006
First Quarter Second Quarter Third Quarter YTD Percent Of Sales First Quarter Second Quarter Third Quarter YTD
Sales 41,621 40,073 46,202 127,896 100% 4,022 2,376 3,189 9,587
Intersegment sales (5,699) (6,647) (7,072) (19,418)   (400) (92) (676)  (1,168)
35,922 33,426 39,130 108,478   3,622 2,284 2,513 8,419
                 
Cost of sales 8,482 7,683 9,041 25,206 20% 12 (464) (84) (536)
Intersegment sales (5,524) (6,435) (7,147) (19,106)   (201) (295) (669)  (1,165)
2,958 1,248 1,894 6,100   (189) (759) (753) (1,701)
                 
Gross margin 32,964 32,178 37,236 102,378 80% 3,811 3,043 3,266 10,120
                 
Gross margin percentage 79.6% 80.8% 80.4% 80.3%          
                 
SG&A expense 4,013 4,664 4,166 12,843 10% 374 470 (33) 811
R&D expense 4,675 4,854 4,971 14,500 11% 143 450 378 971
Amortization expense 403 404 403 1,210 2% (89) (88) (89) (266)
Interest, net (595) (722)  (841) (2,158) (2%) (327) (349) (556)  (1,232)
8,496 9,200  8,699 26,395 21% 101 483 (300)      284
Pretax result 24,468 22,978 28,537 75,983 59% 3,710 2,560 3,566   9,836

(1) Includes R&D Systems' Biotechnology Division, Fortron Bio Science, Inc., and BiosPacific, Inc.

Back to Top
R&D SYSTEMS EUROPE
(in thousands of £'s) 

  Fiscal 2007 Increase(Decrease) From Fiscal 2006
First Quarter Second Quarter Third Quarter YTD Percent Of Sales First Quarter Second Quarter Third Quarter YTD
Sales 6,870 7,851 8,854 23,575 100% 180 322 598 1,100
Cost of sales 3,285 3,766 4,091  11,142   47% (7) 1 (100)  (106)
Gross margin 3,585 4,085 4,763 12,433 53% 187 321 698 1,206
                 
Gross margin percentage 52.2% 52.0% 53.8% 52.7%        
             
SG&A expense 1,074 1,236 1,075 3,385 14% 70 51 5 126
Interest income (410) (480) (542) (1,432) (6%) (84) (151) (200) (435)
Exchange loss/(gain) 78 (64) 22 36 -- 63 (90)     71      44
742 692     555   1,989    8% 49 (190) (124) (265)
Pretax result 2,843 3,393  4,208 10,444  45% 138 511  822 1,471

Back to Top
R&D SYSTEMS EUROPE
(in thousands of $’s)

  Fiscal 2007 Increase(Decrease) From Fiscal 2006
First Quarter Second Quarter Third Quarter YTD Percent Of Sales First Quarter Second Quarter Third Quarter YTD
Sales 12,927 15,257 17,403 45,587 100% 1,052 2,151 2,907 6,110
Cost of sales 6,181 7,319  8,040  21,540   47% 337 765    682 1,784
Gross margin 6,746 7,938 9,363 24,047 53% 715 1,386 2,225 4,326
             
Gross margin percentage 52.2% 52.0% 53.8% 52.7%        
           
SG&A expense 1,782 2,405 2,112 6,537 14% 238 346 233 817
Interest income (771) (933) (1,067) (2,771) (6%) (192) (361) (467) (1,020)
Exchange loss 147
  		(126) 42 63 -- 119 (172)   129      76
1,396 1,346  1,087   3,829     8% 165 (187) (105)  (127)
Pretax result 5,350 6,592 8,276 20,218   45% 550 1,573 2,330 4,453

Back to Top
CORPORATE AND OTHER (2)
(in thousands of $’s)

  Fiscal 2007 Increase(Decrease) From Fiscal 2006
First Quarter Second Quarter Third Quarter YTD First Quarter Second Quarter Third Quarter YTD
Interest income 229 206 218 653 139 71 61 271
Rental income 299 241     55      595 (43) (96) (232)    (371)
528 447 273 1,248 96 (25) (171) (100)
           
SG&A expense 636 1,322 520 2,478 (13) 19 138 144
Interest expense 268 815 0 1,083 45 577 (245) 377
Other-Building expenses 510 549 519 1,578 67 59 (1) 125
Other-Hemerus losses 127 123 119 369 45 41 36 122
Other-Nephromics losses -- 123    142      265 -- 123  142      265
  1,541 2,932 1,300   5,773 144 819   70 1,033
Pretax result (1,013) 3,393 (1,027) (4,525) 42% 138 (241) (1,133)

Back to Top

(2) Unallocated corporate expenses and Techne’s share of losses by Hemerus Medical, LLC and Nephromics, LLC.